SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Tissue Plasminogen Activator + Gas and Macular Translocation in Treatment of Subretinal Hemorrhage

Subretinal Kanamada Doku Plazminojen Aktivatörü + Gaz ve Maküla Translokasyon Cerrahileri

Levent KARABAŞ
Berna ÖZKAN
Pages
205–210
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, we summarized the treatment algorythm that we use in our clinic in patients with subretinal hemorrhage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Subretinal Hemorrhage causes sudden decrease in vision, and may cause irreversible loss in visual acuity when it is large and persistent.
📊
Key Findings & Data:There are many clinical and experimental studies related with the treatment methods and treatment timing of subretinal hemorrhage.
💡
Conclusion & Impact:Additionally, we summarized the treatment algorythm that we use in our clinic in patients with subretinal hemorrhage.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Subretinal Hemorrhage causes sudden decrease in vision, and may cause irreversible loss in visual acuity when it is large and persistent. There are many clinical and experimental studies related with the treatment methods and treatment timing of subretinal hemorrhage. Reported treatments include retinal pigment epithelial and choroid patch, macular translocation, pneumatic displacement, intravitreal or subretinal tissue plas- minogen activator, intravitreal anti-vascular endothelial growth factor (VEGF) drugs, and combinations thereof. The aim of our review is to discuss the recommended treatment methods in sub- retinal hemorrhage. Additionally, we summarized the treatment algorythm that we use in our clinic in patients with subretinal hemorrhage.

Özet

Subretinal kanama ani görme kayıpları ile kendini gösteren, yoğun ve uzun süreli olduklarında görme keskinliğinin kalıcı olarak etkilenmesine yol açabilen bir hastalıktır. Subretinal ka- nama tedavisinde seçilecek yöntem ve tedavinin zamanlaması ile ilgili literatürde bir çok farklı klinik ve deneysel çalışma bu- lunmaktadır. Bunlar arasında retina pigment epiteli ve koroid yaması, maküler translokasyon, pnömatik yer değiştirme, intra- vitreal veya subretinal doku plazminojen aktivatörü (TPA), int- ravitreal vasküler endotelyal growth faktör inhibitörü (anti-VE- GF) ve bunların kombinasyonları sayılabilir. Biz de bu derlemede subretinal kanama için önerilen tedavi yöntemlerini tartışmayı amaçladık. Ayrıca kliniğimizde karşılaştığımız farklı şiddetteki subretinal kanama hastalarına ne şekilde yaklaştığımızı özetle- meye çalıştık.

🔖

Cite This Article

KARABAŞ, L., ÖZKAN, B. (2017). Tissue Plasminogen Activator + Gas and Macular Translocation in Treatment of Subretinal Hemorrhage. Retina-Vitreus, Cilt: 26 - Sayı: 0, 205–210. https://ajindex.com/articles/304864

References (10)

  1. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762-73
  2. Fine HF, Iranmanesh R, Del Priore LV, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. 2010;30:1588e94 Shin JY, Lee JM, Byeon SH. Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. 2015 May;159(5):904-14
  3. Fujikawa M, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Sakaguchi H, Gomi F, Ohji M. Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina. 2013 Oct;33(9):1908-14.
  4. Çakır M, Çekiç O, Yılmaz OF. Pneumatic displacement of acute submacular hemorrhage with and without the use of tissue plas- minogen activator. Eur J Ophthalmol 2010;20(3):565-71.
  5. Fang IM, Lin YC, Yang CH, Yang CM, Chen MS. Eff ects of intra- vitreal gas with or without tissue plasminogen activator on sub- macular haemorrhage in age-related macular degeneration. Eye. 2009 Feb;23(2):397-406. van Zeeburg EJ, van Meurs JC. Literature review of recombi- nant tissue plasminogen activator used for recent-onset subma- cular hemorrhage displacement in age-related macular degene- ration. Ophthalmologica. 2013;229(1):1-14.
  6. Stanescu-Segal D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Surv Ophthalmol 2016;61(1):18-32.
  7. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237:273e7 Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasmi- nogen activator injection and pneumatic displacement. Ophthal- mology. 1999;106:1900-6.
  8. Tsai SC, Lin JM, Chen HY. Intravitreous recombinant tissue plasminogen activator and gas to treat submacular hemorrha- ge in age-related macular degeneration. Kaohsiung J Med Sci. 2003;19:608e16 Pertile G, Claes C. Macular translocation with 360 degree re- tinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2002;134(4):560-5.
  9. Park CH, Toth CA. Macular translocation surgery with 360-deg- ree peripheral retinactomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2003;136(5):830-5
  10. Wong D, Stanga P, Briggs M, et al. Case